Icosavax IncNASDAQ ICVX Stock Report

Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable the multivalent, particle-based display of complex viral antigens. The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus. It is conducting a Phase I/II clinical trial of its coronavirus disease 2019 (COVID-19) candidate IVX-411 in Australia. It is conducting further analysis of the data and its IVX-411 vaccine candidate, including an investigation into the manufacture, shipment and vaccine administration in Phase I/II clinical trial.